How do we identify and treat patients with BRAF-mutated mCRC?
How do we identify and treat patients with BRAF-mutated mCRC?
Asst. Prof. Joleen Hubbard, Prof. Armin Gerger
Dr. Scott Kopetz (USA) led a very interesting and interactive GI CONNECT virtual Experts Knowledge Share which addressed the question ‘How do we identify and treat patients with BRAF-mutated mCRC (metastatic colorectal cancer) today and tomorrow?' Dr. Armin Gerger and Dr. Joleen Hubbard provided the US and European perspectives on this important topic.Asst. Prof. Joleen Hubbard
Medical Oncologist
Mayo Cinic Rochester
United States (US)
Asst. Prof. Joleen Hubbard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Armin Gerger
Medical Oncologist
Medical University of Vienna
Austria
Prof. Armin Gerger has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
| 5 min | Oct 2020
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.